<DOC>
	<DOC>NCT00948909</DOC>
	<brief_summary>This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.</brief_summary>
	<brief_title>Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease</brief_title>
	<detailed_description>This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in approximately 260 adults with mild-to-moderate Alzheimer's disease (AD). Subjects will be randomized to one of the four treatment groups (ABT-126, donepezil, or placebo) for a 12-week Treatment Period. Acronyms are listed in the secondary outcome section, below, you will find a list of the acronyms defined: - MMSE - Mini Mental Status Exam - QoL-AD - Quality of Life - Alzheimer's Disease - CIBIC-plus - Clinician Interview-Based Impression of Change - NPI - Neuropsychiatric Inventory - CSDD - The Cornell Scale for depression in Dementia - ADCS-ADL - Alzheimer's Disease Cooperative Study - Activities of Daily Living</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1. The subject meets the NINCDS/ADRDA criteria for probable AD. The subject has a MiniMental Status Examination (MMSE) total score of 10 to 24, inclusive, at Screening Visit 1. The subject has a Modified Hachinski Ischemic Scale (MHIS) score of less than or equal to 4 at Screening Visit 1. If female, subject must be postmenopausal for at least two years or surgically sterile The subject has an identified, reliable, caregiver. The subject is currently taking or has taken a medication for the treatment of Alzheimer's disease or dementia within 60 days prior to Screening Visit 1 The subject has a history of any significant neurologic disease other than AD. In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness. The subject has reported history of discontinuation of donepezil due to lack of efficacy. The subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation. The subject has a known hypersensitivity to donepezil, piperidine derivatives, or any of the excipients in either donepezil hydrochloride or ABT126 formulations. Patient uses nonprescribed drugs of abuse or has a history of drug or alcohol abuse/dependence. Subjects with AST and ALT values at Screening Visit 1 that are greater than or equal to 1.5fold the upper limit of normal (ULN).</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>